← 返回

GRHL3 通过 RNF2 驱动肺鳞状细胞癌的放疗抵抗并阻断 NK 和 CD4(+) T 细胞的抗肿瘤反应

英文原题:GRHL3 drives radiotherapy resistance and blocks the anti-tumor response of NK and CD4(+) T cells in lung squamous cell carcinoma via RNF2.

查看英文原题

GRHL3 drives radiotherapy resistance and blocks the anti-tumor response of NK and CD4(+) T cells in lung squamous cell carcinoma via RNF2.

PubMed 2025/01/27(内容时间) Biochem Pharmacol Q1 · IF 6.5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

Grainyhead样蛋白3同源物(GRHL3)已被确定为与肺鳞状细胞癌(LUSC)角化相关的重要转录因子。我们设计本研究以阐明GRHL3在LUSC放射抵抗中的功能及其相关机制。通过分析放射抵抗细胞与亲本细胞之间的转录组差异,以鉴定核心转录因子。相对于亲本细胞,GRHL3在放射抵抗细胞中表达上调,而敲低GRHL3可使放射抵抗LUSC细胞恢复敏感性,诱导DNA损伤,抑制细胞存活,并减少小鼠体内的肿瘤负荷。GRHL3通过结合RNF2启动子促进环指蛋白2(RNF2)转录。GRHL3诱导亲本细胞产生放射抵抗表型,并导致CD4+ T细胞和NK细胞的抗肿瘤免疫应答受损。GRHL3促进的肿瘤进展可被敲低RNF2所逆转。放射抵抗细胞中GRHL3的DNA甲基化降低。总而言之,由于GRHL3帮助LUSC细胞逃避免疫监视并介导放射抵抗,它可能是治疗耐药性LUSC的一个有吸引力的靶点。

展开英文摘要原文

Grainyhead-like protein 3 homolog (GRHL3) has been identified as a top transcription factor associated with keratinization in lung squamous cell carcinoma (LUSC).

We designed this study to elucidate the function of GRHL3 in radioresistance in LUSC and the mechanism involved. Transcriptome differences between radioresistant and parental cells were analyzed to identify the hub transcription factor. GRHL3 expression was overexpressed in radioresistant cells relative to parental cells, and the knockdown of GRHL3 conferred sensitivity to radioresistant LUSC cells, induced DNA damage, inhibited cell survival, and reduced tumor load in mice.

GRHL3 promoted ring finger protein 2 (RNF2) transcription by binding to the RNF2 promoter. GRHL3 induced a radioresistant phenotype in parental cells and led to compromised anti-tumor immune responses of CD4 + T cells and NK cells. The GRHL3-promoted tumor progression was reversed by the knockdown of RNF2. The DNA methylation of GRHL3 was reduced in radioresistant cells. All in all, as GRHL3, helps LUSC cells escape from the immune surveillance and mediates radioresistance, it might be an attractive target for therapy-resistant LUSC.

论文信息

作者
Wang H、Liu C、Jiang C、Zhang Y、Zhao X、Jia Z、Huo J、Yang J
第一作者单位
Department of Thoracic Surgery, Xingtai People's Hospital, Xingtai 054000 Hebei, PR China.China
通讯作者单位
Department of Radiotherapy, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050000 Hebei, PR China. Electronic address: doctoryangj@hebmu.edu.cn.China
文献类型
非美国政府资助研究
期刊
Biochemical pharmacology2025 Mar
原文标识
PubMed 39880318 · DOI 10.1016/j.bcp.2025.116784